Tina C. Young

1.9k total citations · 1 hit paper
18 papers, 1.1k citations indexed

About

Tina C. Young is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Tina C. Young has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Immunology. Recurrent topics in Tina C. Young's work include Cancer Immunotherapy and Biomarkers (12 papers), Renal cell carcinoma treatment (3 papers) and CAR-T cell therapy research (3 papers). Tina C. Young is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Renal cell carcinoma treatment (3 papers) and CAR-T cell therapy research (3 papers). Tina C. Young collaborates with scholars based in United States, Canada and Spain. Tina C. Young's co-authors include Hossein Borghaei, Scott A. Laurie, Scott Antonia, Laura Q.M. Chow, Jonathan W. Goldman, Frances A. Shepherd, Rosalyn A. Juergens, Matthew D. Hellmann, William J. Geese and Julie R. Brahmer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Tina C. Young

18 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

2016 700 citations Matthew D. Hellmann, Naiyer A. Rizvi et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Tina C. Young

Since Specialization

Citations

This map shows the geographic impact of Tina C. Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tina C. Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tina C. Young more than expected).

Fields of papers citing papers by Tina C. Young

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tina C. Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tina C. Young. The network helps show where Tina C. Young may publish in the future.

Co-authorship network of co-authors of Tina C. Young

This figure shows the co-authorship network connecting the top 25 collaborators of Tina C. Young. A scholar is included among the top collaborators of Tina C. Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tina C. Young. Tina C. Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma 2021 ·Cancer Immunology Research ·F. Stephen Hodi, Jedd D. Wolchok, Dirk Schadendorf, James Larkin, Georgina V. Long, Xiaozhong Qian, Abdel Saci, Tina C. Young, Sujaya Srinivasan, Han Chang, Hao Tang, Megan Wind‐Rotolo, Jasmine I. Rizzo, Donald Jackson, Paolo A. Ascierto	76
2	P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073 2021 ·Annals of Oncology ·Bruno Sangro, Kazushi Numata, Yi‐Hsiang Huang, Carlos Gómez-Martín, Atsushi Hiraoka, Michihisa Moriguchi, Ying‐Chun Shen, Andrea Horváth, William F. Feely, Tina C. Young, Jaclyn Neely, Masatoshi Kudo	11
3	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920. 2019 ·Journal of Clinical Oncology ·Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson, Richard J. Lee, Tina C. Young, Jennifer L. Johansen, Scott S. Tykodi	27
4	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma 2019 ·Clinical Trials ·F. Stephen Hodi, Jedd D. Wolchok, Dirk Schadendorf, James Larkin, (unknown), Abdel Saci, Tina C. Young, Sujaya Srinivasan, Chang Han, Megan Wind‐Rotolo, Jasmine I. Rizzo, Donald Jackson, Paolo A. Ascierto	4
5	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma 2019 ·Cancer Research ·F. Stephen Hodi, Jedd D. Wolchok, Dirk Schadendorf, James Larkin, (unknown), Abdel Saci, Tina C. Young, Sujaya Srinivasan, Han Chang, Megan Wind‐Rotolo, Jasmine I. Rizzo, Donald Jackson, Paolo A. Ascierto	14
6	Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC 2018 ·Journal of Thoracic Oncology ·Scott Gettinger, Matthew D. Hellmann, Laura Q.M. Chow, Hossein Borghaei, Scott Antonia, Julie R. Brahmer, Jonathan W. Goldman, David E. Gerber, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, Tina C. Young, Xuemei Li, William J. Geese, Naiyer A. Rizvi	150
7	OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012 2017 ·Journal of Thoracic Oncology ·Scott Gettinger, Naiyer A. Rizvi, Laura Q.M. Chow, Hossein Borghaei, Julie R. Brahmer, Frances A. Shepherd, Neal Ready, David E. Gerber, Scott Antonia, Jonathan W. Goldman, Rosalyn A. Juergens, William J. Geese, Tina C. Young, Xuemei Li, Matthew D. Hellmann	9
8	A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials 2017 ·The Journal of Clinical Pharmacology ·Tina C. Young, Subasree Srinivasan, Marion Vetter, Venkat Sethuraman, Zubin Bhagwagar, Ricardo Zwirtes, (unknown), (unknown), Brendan Smyth	6
9	OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update 2017 ·Journal of Thoracic Oncology ·Rosalyn A. Juergens, Matthew D. Hellmann, Julie R. Brahmer, Hossein Borghaei, Scott Gettinger, Laura Q.M. Chow, David E. Gerber, Scott A. Laurie, Jonathan W. Goldman, Frances A. Shepherd, William J. Geese, Tina C. Young, (unknown), Scott Antonia	14
10	Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038 2017 ·Cancer Research ·Antoni Ribas, Salvador Martín‐Algarra, Shailender Bhatia, Wen‐Jen Hwu, Craig L. Slingluff, William H. Sharfman, F. Stephen Hodi, Walter J. Urba, Jason J. Luke, John B.A.G. Haanen, Margaret K. Callahan, Jedd D. Wolchok, Scott D. Chasalow, Petra Ross‐Macdonald, Tina C. Young, Anila Qureshi, Christine E. Horak	2
11	ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC 2016 ·Journal of Thoracic Oncology ·Scott Antonia, Scott Gettinger, Jonathan H. Goldman, Julie R. Brahmer, Hossein Borghaei, Laura Q.M. Chow, Neal Ready, David E. Gerber, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, Tina C. Young, William J. Geese, Shruti Agrawal, Xuemei Li, Matthew D. Hellmann	9
12	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study breakdown → 2016 ·The Lancet Oncology ·Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal Ready, David E. Gerber, Laura Q.M. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott Antonia	700
13	Diagnosis and Treatment of Acute Gout at a University Hospital Emergency Department 2015 ·The Open Rheumatology Journal ·Naomi Schlesinger, Diane C. Radvanski, Tina C. Young, Jonathan V. McCoy, (unknown), Dirk F. Moore	6
14	The Effect of Furosemide Dose Administered in the Out-of-hospital Setting on Renal Function Among Patients with Suspected Acute Decompensated Heart Failure 2015 ·Prehospital and Disaster Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tina C. Young, Mark A. Merlin	1
15	Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. 2015 ·Journal of Clinical Oncology ·Toni K. Choueiri, Mayer Fishman, Bernard Escudier, David F. McDermott, Harriet M. Kluger, Walter M. Stadler, José Luis Perez‐Gracia, Douglas G. McNeel, Brendan D. Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard J. Appleman, Lawrence Fong, Charles G. Drake, Tina C. Young, Scott D. Chasalow, Petra Ross‐Macdonald, Jason S. Simon, Damian Walker, Mario Sznol	21
16	Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab 2015 ·Journal for ImmunoTherapy of Cancer ·Mario Sznol, Mayer Fishman, Bernard Escudier, David F. McDermott, Harriet M. Kluger, Walter M. Stadler, José Luis Perez‐Gracia, Douglas G. McNeel, Brendan D. Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard J. Appleman, Lawrence Fong, Charles G. Drake, Tina C. Young, Scott D. Chasalow, Petra Ross‐Macdonald, Jason S. Simon, Damian Walker, Toni K. Choueiri	1
17	629 2014 ·Critical Care Medicine ·Justin Kaplan, (unknown), (unknown), Tina C. Young, (unknown), Gregg R. Klein	1
18	Deposition of sulfuric acid mists in the respiratory tract of beagle dogs 1983 ·Journal of Toxicology and Environmental Health ·Alan R. Dahl, M.B. Snipes, Bruce A. Muggenburg, Tina C. Young	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact